comprehensive -WSS

comprehensive

author：explore 2025-10-04 06:39:24 - browse：3

New Sanofi Genzyme president Bill Sibold is the first person without any ties to Henri Termeer (inset) to lead the company. Jonathan Wiggs/Globe staff

CAMBRIDGE, Mass. — When drug giant Sanofi restructured its global business two years ago, its Genzyme division got a new name, Sanofi Genzyme, explicitly tying it to the French parent company. It also got new responsibilities and a larger “specialty care” portfolio covering everything from enzyme replacement to cancer and multiple sclerosis drugs.

Last week, Sanofi Genzyme — still the largest Massachusetts biotech, with about 5,000 workers — also got a new president, Bill Sibold. He’s the first one without any ties to the old Genzyme, an independent company that pioneered the rare-disease business model and catalyzed the local life sciences boom before accepting Sanofi’s $20.1 billion takeover offer in 2011.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Grad students accuse University of California of wage theft

Wikipedia

explore

WSS

Why the drug industry's warnings on the IRA's impact fall short

Vertex non

Vertex non

People with substance use disorder deserve online privacy

Akili changes sales model for its ADHD video game treatment

Grad students accuse University of California of wage theft

focus

comprehensive

explore

Tori Bowie and the unacceptable rates of Black maternal death

White House pharmacy plagued with problems, investigation finds

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Eli Lilly CEO gives to Mike Pence presidential super PAC

New air purifier tech could be key to improving indoor air quality

The unintended consequences of overturning Roe v. Wade

Alkermes shareholders re

10 reasons why health care startups fail

Medical records are filled with copy

The struggle to figure out which patients 'deserve' Wegovy

hotspot

Medicare Advantage insurers face 0.2% cut to 2025 payments

Reconstructing family trees of blood cells may help predict disease

Philips to halt sales of sleep apnea machines in U.S.

Humana’s losses in Medicare Advantage tank its stock

New clues to why women have higher risk of autoimmune disorders

Information blocking fines are now fair game in health care

hotspot

Wikipedia

explore

knowledge